Demand for New analgesics for muscle and joint pain

The "TOP 10 Global Pharma Company" is seeking:

New topical analgesics, or superior delivery of existing topical analgesics, for the relief of muscle and joint pain.

They are looking for potential partners with unique innovative technologies to meet changing needs of global consumers. Seeker is the leading research-based pharmaceutical and healthcare company , employing  100,000+  people in 100+  countries. 

Your product innovation combined with additional scientific expertise and world-class marketing can help them deliver innovative Consumer Healthcare brands around the world.  Seeker is committed to Open Innovation R&D  model.

Open Innovation is process for linking of external ideas or innovative technology with internal R&D and commercial team responsible to grow new innovative and branded products..

First you should  submit non-coofidential information about your innovative product or technology. Once submitted, your innovation idea is assigned to an Technology Transfer Manager at Farmavita.Net to guide the idea through early stage of assessment. After positive initial assessment  you will be asked for an agency agreement with Farmavita.Net, to authorize us to manage you thorough the process of licensing negotiations. 

Contact us for more details or to submit your non-confidential proposal!   

Comments

Add New Search RSS

Michel Lockhart  - Topical Analgesic   |Author |2009-05-26 14:53:51 The product is ready for market with proven success in the US market. It is a topical analegesic that utilizes a high concentration of methyl salicylate 40% (MeSA) that is delivered utilizing a highly lippohphilic delievery formulation that provides a synergistic effect with the MeSA. Mode of Action Direct subcutaneous absorption to deeper tissue and structures; muscles, tendons, ligaments, joint capsules, and synovial fluid. Delivers high concentrations of active ingredient to site with minimal blood absorption. Mechansism of Action Anti-inflammatory - Local inhibition of prostaglandins. Analegesic - ASA type action locally- under the site of application. 3. Counter-irrittant - warming sensation on the skin at site of application. Successful Market Position: A alternative and/or adjunct to oral NSAI Ds. Superior clinical efficacy to other topicals due to its absorption to deeper tissue: More drug to site. More drug faster to site. Please let me how you may like to proceed. Michel Lockhart Reply

Write comment
Name:
Email:	do not notifynotify
Website:
Title:
	Please input the anti-spam code that you can read in the image.

Powered by !JoomlaComment 3.26

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

• Continued Support for Innovation (03/05/2013)
• Market & Patient Access (17/04/2013)
• New Joint Health Supplement (15/01/2013)

• Inlicensing opportunities (06/08/2009)
• Agency and distribution partership (24/06/2009)
• Tooth Surface Protection (14/02/2009)

• Pain Management, Arthritis and Gynaecology Segment (02/06/2008)
• Urology products demand (04/01/2008)
• Innovative NCE (16/06/2006)